Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways
-
- S Michael Rothenberg
- Cancer Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States
-
- Kyle Concannon
- Cancer Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States
-
- Sarah Cullen
- Cancer Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States
-
- Gaylor Boulay
- Cancer Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States
-
- Alexa B Turke
- Cancer Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States
-
- Anthony C Faber
- Cancer Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States
-
- Elizabeth L Lockerman
- Cancer Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States
-
- Miguel N Rivera
- Cancer Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States
-
- Jeffrey A Engelman
- Cancer Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States
-
- Shyamala Maheswaran
- Cancer Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States
-
- Daniel A Haber
- Cancer Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States
説明
<jats:p>Treatment of <jats:italic>EGFR</jats:italic>-mutant lung cancer with erlotinib results in dramatic tumor regression but it is invariably followed by drug resistance. In characterizing early transcriptional changes following drug treatment of mutant EGFR-addicted cells, we identified the stem cell transcriptional regulator SOX2 as being rapidly and specifically induced, both in vitro and in vivo. Suppression of SOX2 sensitizes cells to erlotinib-mediated apoptosis, ultimately decreasing the emergence of acquired resistance, whereas its ectopic expression reduces drug-induced cell death. We show that erlotinib relieves EGFR-dependent suppression of FOXO6, leading to its induction of SOX2, which in turn represses the pro-apoptotic BH3-only genes <jats:italic>BIM</jats:italic> and <jats:italic>BMF</jats:italic>. Together, these observations point to a physiological feedback mechanism that attenuates oncogene addiction-mediated cell death associated with the withdrawal of growth factor signaling and may therefore contribute to the development of resistance.</jats:p>
収録刊行物
-
- eLife
-
eLife 4 2015-02-16
eLife Sciences Publications, Ltd